Researchers at the University of Colorado have found that histone deacetylase 11 (HDAC11) inhibitors may be a treatment for metabolic syndrome and obesity-related conditions. In mice, they found that compared with wildtype (WT) controls, animals lacking HDAC11 were lean and displayed enhanced production of metabolically active BAT. HDAC11-deficient mice were also healthy and exhibited reduced weight gain and lipid accumulation in response to high-fat feeding, and improved glucose tolerance. These results suggest that HDAC11 inhibitors may be an innovative new treatment option for obesity and a variety of related conditions, including diabetes and NASH.